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Abstract
Objective: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anti-
cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive
protein (CRP) in patients with erosive and non-erosive rheumatoid arthritis (RA).
Methods: We assembled a training set, consisting of 60 patients with RA, all fulﬁlling the revised criteria of the American
College of Rheumatology. A commercial enzyme linked immunosorbent assay (ELISA) was used both to test for anti-CCP
antibodies (second generation ELISA kit) and MMP; RF were detected by latex-enhanced immunonephelometric assay. CRP
was measured by latex turbidimetric immunoassay.
Results: The levels of anti-CCP antibody titers and ESR were signiﬁcantly higher in patients with erosive disease than those
in non-erosive RA patients (p , 0.001 and 0.0341) respectively. Moreover, a higher frequency of elevated titers of anti-CCP
antibodies was found in RA patients with erosions compared to patients with non-erosive RA (78.3% vs. 43.2% respectively).
The ROC curves of anti-CCP passed closer to the upper left corner than those other markers and area under the curve (AUC)
of anti-CCP was signiﬁcantly larger than AUC of other markers (0.755 for anti-CCP, 0.660 for ESR, 0.611 for CRP, 0.577 for
RF, and 0.484 for MMP-3 female).
A positive predictive value was higher for anti-CCP antibodies in comparison to other markers. We did not ﬁnd signiﬁcant
statistical correlation between anti-CCP antibody titers and inﬂammatory markers such as ESR or CRP. However, we
conﬁrmed the correlation of elevated titers of anti-CCP antibodies and RF in both groups of patients whereas the degree of
correlation was more signiﬁcant in non-erosive patients.
Conclusion: The results of our study suggest that the presence of elevated anti-CCP antibody titers have better diagnostic
performance than MMP-3, RF, CRP and ESR in patients with erosive RA.
Keywords: Rheumatoid factor (RF), anti-CCPantibodies, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR),
rheumatoid arthritis (RA)
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease of unknown etiology, distinguished by chronic
inﬂammation of joints resulting in tissue degradation
and joint deformation. The course of RA is varied
ranging from a mild to an aggressive form. Early
diagnosis and treatment reduce joint destruction,
preserve function and improve survival (Subcommit-
tee 2002).
The link between chronic inﬂammation and joint
damage has been widely established, especially the
relevance of inﬂammatorymarkers such as erythrocyte
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(CRP) (Graudal et al. 2000, Plant et al. 200l).
However, the damage may progress in spite of
decreased inﬂammatory activity and erosions may
develop in patients without clinical sings of signiﬁcant
inﬂammation (Kirwan 1997, van den Berg 2001).
Therefore, an identiﬁcation of reliable predictors and
markers of joint damage is necessary.
In the present study, we selected several laboratory
variables and tested their prognostic value in a well
deﬁned cohort of patients with erosive and non-
erosive RA. The variables were ESR and CRP,
reﬂecting inﬂammation; matrix metalloproteinase-3
(MMP-3), which is involved in matrix degradation
and cartilage turnover and a set of autoantibodies:
rheumatiod factor (RF) and anti-cyclic citrullinated
peptide antibody (anti-CCP).
MMP-3 plays an important role in the pathogenesis
of matrix degradation in RA, including proteoglycans,
gelatins, laminin, ﬁbronectin and collagen (Okada
et al. 1987). An over-expression of MMP-3 in synovial
ﬂuid, rheumatoid synovium and cartilage as well as an
increased level of MMP-3 in the serum obtained from
RA patients clearly reﬂects the contribution of MMP-
3 in chronic inﬂammation and joint destruction
(Manicourt et al. 1995, Yoshihara et al. 1999). In
addition, serum MMP-3 levels correlate with clinical
activity of RA (Keyszer et al. 1999, So et al. 1999).
The data regarding the relevance of serum MMP-3
levels and the presence of joint erosions remains
controversial (So et al. 1999, Posthumus et al. 2000).
RA is associated with elevated titers of antibodies,
including RF, anti-CCP, antibodies directed against
RA-33, calpastatin, keratin and antiﬁlaggrin; most of
these have failed to demonstrate adequate diagnostic
and prognostic value (Goldbach-Mansky et al. 2000).
RF, an autoantibody directed against the constant
region of IgG is elevated in 75% of patients with RA
and widely used in clinical practice. In addition to
RF, anti-CCP antibodies are frequently observed in
patients with RA, especially in early disease (Ranta-
paa-Dahlqvist et al. 2003, Nielen et al. 2004). It has
been reported that elevated titers of anti-CCP
antibodies are more speciﬁc for RA than RF with a
disease speciﬁcity approaching 100% (Schellekens
et al. 2000). Both of these serological markers are
associated with more severe joint damage (Visser et al.
2002, Orbach et al. 2002, Vencovsky et al. 2003,
Meyer et al. 2003, Forslind et al. 2004). The
comparison of diagnostic utility of anti-CCP, RF and
MMP-3 in patients with RA and other autoimmune
diseases suggest that anti-CCP proved to be superior
to RF and MMP-3 (Suzuki et al. 2003). A high
disease speciﬁcity of anti-CCP coupled with reason-
able sensitivity and high predictive value for RA
progression and radiological damage suggest that
anti-CCP may play an important role in RA
pathogenesis.
The objective of this study was to compare the
diagnostic utility of laboratory variables, including
MMP-3, anti-CCP antibodies, RF, ESR and CRP in
60 samples, collected from patients with erosive and
non-erosive RA.
Patients and methods
Patients
Sixty patients with RA, all fulﬁlling the revised criteria
of the American College of Rheumatology were
included in the study. Serum samples were obtained
from Dr R. Gerli (Universita Di Perugia, Italy). The
patients were divided into two groups: erosive and
non-erosive disease according to the presence of
erosions on X-ray.
The median disease duration of RA was 5–10 years.
Twenty three patients (15 female and 8 male) had
erosive disease and 37 (29 female and 8 male) had
non-erosive disease. The median age of the patients
was 62 and 60 years in the ﬁrst and second group,
respectively.
All patients’ sera were tested for anti-CCP, RF,
MMP-3, CRP, and ESR.
Methods
Anti-CCP antibody titers was detected using a
commercial Quanta Lite CCP ELISA anti-CCP 2
kit (INOVA Diagnostics, San Diego, CA, USA). The
optimal cut-off value for anti-CCP ELISA was
20U/ml.
RF was measured by latex-enhanced immuno-
nephelometric assay (Dede Behring, Marburg,
Germany). The cut-off value for RF was 15IU/ml.
MMP-3 was measured by ELISA (The Binding Site
Limited, Birmingham, UK). The cut-off values for
MMP-3 were 45.3ng/ml for males and 21.0ng/ml for
females. CRP was measured by latex turbiimetric
immunoassay (Medical and Biological Laboratories,
Nagoya, Japan). ESR was measured by Westergren
method.
Statistical analysis
Comparison of the level distributions of anti-CCP,
RF, MMP-3, ESR and CRP in patients with erosive
and non-erosive disease was made using the Mann
Whitney U test. Differences between groups of
patients were considered signiﬁcant when P values
were , 0.05. Comparisons of sensitivity and
speciﬁcity were made using McNemar’s test.
For the construction of ROC curves, relations
between sensitivity (ordinate) and speciﬁcity
(abscissa) for various cut-off points were plotted. In
general, a closer location of the ROC plot to the upper
left corner indicates a higher diagnostic performance
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provides an index of the overall discriminative ability
of the test. The comparison of AUC was performed
utilizing the Statistical Package SPSS. Pearson’s
correlation coefﬁcient assessed the importance of the
different variables. Differences were considered
signiﬁcant if p , 0.05. The determination of the
predictive value was done by MedCalc Software.
Results
Serum levels of anti-CCP, MMP-3, RF, CRPand ESR in
RA patients with erosive and non-erosive disease
We examined the levels of anti-CCP, MMP-3, RF,
CRP and ESR level in RA patients with erosive and
non-erosive disease (Table I). The levels of anti-CCP
antibody titers and ESR were signiﬁcantly higher in
patients with erosive disease than those with non-
erosive disease (p , 0.001 and 0.0341 respectively).
Moreover, the higher frequency of elevated anti-
CCP antibody titers was found in RA patients with
erosions compared to the value in patients with non-
erosive RA (78.3% vs. 43.2%) (Table II).
Clinical sensitivity and speciﬁcity of anti-CCP, MMP-3,
RF, CRP and ESR
Elevated titers of anti-CCP antibodies had a
speciﬁcity and sensitivity of 70.3% and 73.9%,
respectively for erosive RA compared to non-erosive
disease (Table III). This clinical speciﬁcity of anti-
CCP antibodies was superior to RF, ESR, CRP and
MMP (Table III). For further comparison of the
diagnostic utilities of each tests, we constructed ROC
curves and calculated the AUC. The ROC curves of
anti-CCP passed closer to the upper left corner than
the other markers indicating that the sensitivity
compared at the same speciﬁcity value, was higher
for anti-CCP antibody titers (Figure 1). The super-
iority of anti- CCP to other markers was conﬁrmed
by comparing AUC, since AUC of anti-CCP was
signiﬁcantly larger than AUC of other markers (area
under the curve was 0.755 for anti-CCP, 0.660 for
ESR, 0.611 for CRP, 0.577 for RF, and 0.484 for
MMP-3 female). Therefore, it appears that anti-
CCP has a higher diagnostic performance for
diagnosis of erosive RA.
Predictive value of anti-CCP, MMP-3, RF, CRP and
ESR
The positive predictive value was higher for anti-CCP
(60.7%) and MMP3 in males (61.5%). The negative
predictive value was higher for MMP3 in males
(100%), CRP (87.5%) and anti-CCP antibody titers
(81.2%). To note, that the high positive and negative
predictive value for MMP 3 was received from a very
small group (8 patients) and can not be statistically
signiﬁcant. Thus, anti-CCP is the best predictor for
erosive disease compared to the other markers
(Table IV).
Table II. Frequency of positive results of MMP3, ESR, RF, anti-
CCP and CRP in patients with erosive and non-erosive RA.
Variable (%) Non-erosive RA Erosive RA
MMP3 female 24.1 40
MMP3 male 37.5 0
ESR 32.4 56.5
RF 45 57
Anti-CCP 43.2 78.3
CRP 21.6 26.1
MMP-3, matrix metalloproteinase 3; ESR, erythrocyte sedimen-
tation rate; RF, rheumatoid factor; Anti-CCP, antibodies against
cyclic citrullinated peptide; CRP, C reactive protein.
Table I. Demographic and laboratory characteristics of patients
with erosive and non-erosive arthritis.
Erosive RA
(n=23)
Non-erosive RA
(n=37)
Age 62.15 (11.28) 60 (12.26)
Sex female 15 29
Sex male 8 8
MMP3 Male (ng/ml) 23.26(14.3) 40.33(40.2)
MMP3 Female (ng/ml) 19.29(22) 17.19(30.89)
ESR (mm/h) 35.65(25.88) 22.49(15.11)
RF (IU/ml) 1.17(0.94) 0.89(0.97)
Anti-CCP (U/ml) 109.58(61.07) 53.25(60.75)
CRP (mg/l) 1.99(3.21) 1.65(2.38)
The results are shown as mean (STDEV); MMP-3, matrix
metalloproteinase 3; ESR, erythrocyte sedimentation rate; RF,
rheumatoid factor; Anti-CCP, antibodies against cyclic citrullinated
peptide; CRP, C reactive protein.
Table III. Determination of sensitivity and speciﬁcity of MMP3, ESR, RF, anti-CCP and CRP in patients with erosive and non-erosive RA.
Variables Criterion Sensitivity (95% C.I.) Speciﬁcity (95% C.I.)
MMP3 Female (ng/ml) 22.570 33.3 (11.9–61.6) 86.2 (68.3–96.0)
MMP3 Male (ng/ml) 49.260 100.0 (100.0–100.0) 37.5 (9.0–75.3)
ESR (mm/hr) 21.000 69.6 (47.1–86.7) 56.8 (39.5–72.9)
RF (IU/ml) 0.000 65.2 (42.7–83.6) 51.4 (34.4–68.1)
Anti-CCP (U/ml) 88.360 73.9 (51.6–89.7) 70.3 (53.0–84.1)
CRP (mg/l) 0.400 91.3 (71.9–98.7) 37.8 (22.5–55.2)
MMP-3, matrix metalloproteinase 3; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; Anti-CCP, antibodies against cyclic
citrullinated peptide; CRP, C reactive protein.
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markers in erosive and non-erosive RA
As shown in Tables V and VI, we did not ﬁnd a
correlation between elevated levels of anti-CCP
antibodies and inﬂammatory markers, including
ESR and CRP in the two groups of RA patients.
In contrast, there was a correlation between levels of
RF and CRP in non-erosive RA. A more signiﬁcant
correlation was seen between elevated anti-CCP
antibody titers and RF in patients with non-erosive
RA (p , 0.001) compared to that in patients with
erosive RA (p , 0.046).
Discussion
Joint damage accounts for a considerable part of
disability caused by RA. Early diagnosis and preven-
tion of joint damage is an important gold standard of
treatment. Hence, an identiﬁcation of the reliable
disease predictors may modify the disease course.
In the present study, we compared the diagnostic
utility of anti-CCP antibodies and other laboratory
markers such as MMP-3, RF IgM, ESR and CRP in
patients with erosive and non-erosive RA. We found
that the levels and the frequency of elevated titers of
anti-CCP antibodies and ESR were higher in patients
with erosive RA. Based on ROC curves analyses, we
demonstrated that the presence of anti-CCP anti-
bodies in patients with erosive RA has a better
diagnostic performance than MMP-3, RF, CRP and
ESR. A positive predictive value was higher for anti-
CCP antibodies in comparison to others markers. We
did not ﬁnd signiﬁcant statistical correlation of anti-
CCP antibodies with inﬂammatory markers such as
ESR and CRP in patients with erosive RA as well as in
patients without erosions. At the same time, we
conﬁrmed a correlation of anti-CCP and RF in both
groups of patients whereas, the degree of correlation
was stronger in non-erosive patients. Thus, the
diagnostic utility of anti-CCP antibodies was superior
toother markersforerosiveRA.Furthermore,absence
of correlation between anti-CCP levels and inﬂamma-
tory markers in patients with erosive disease came out
as an important self-determining marker of erosions.
In recent years interesting data have been accumu-
lated regarding the diagnostic utility of anti-CCP
antibodies in RA patients and their role in the
pathogenesis. Most of clinical utility of this test is
associated with high disease speciﬁcity (Schellekens
et al. 2000) and the presence of anti-CCP antibodies
in early phases of RA (Rantapaa-Dahlqvist et al.
2003). Moreover it has been demonstrated by Nielen
et al. (2004) that the appearance of anti-CCP
antibodies in the circulation may occur several years
before the RA onset and represent a marker of future
disease.
Figure 1. ROC curves of anti-CCP, MMP3 (male and female),
RF, ESR and CRP.
Table IV. Detection of positive and negative predictive values of
MMP3, ESR, RF, Anti-CCP antibodies and CRP in patients with
erosive and non-erosive RA.
Variables Criterion “+PV” “ 2 PV”
MMP3 Female (ng/ml) 22.57 55.6 71.4
MMP3 Male (ng/ml) 49.26 61.5 100.0
CRP (mg/l) 0.40 47.7 87.5
ESR (mm/hr) 21.00 50.0 75.0
RF (IU/ml) 0.00 45.5 70.4
Anti-CCP (U/ml) 88.36 60.7 81.2
MMP-3, matrix metalloproteinase 3; ESR, erythrocyte sedimen-
tation rate; RF, rheumatoid factor; Anti-CCP, antibodies against
cyclic citrullinated peptide; CRP, C reactive protein; þPV—positive
predictive value; 2PV—negative predictive value.
Table V. Pearson correlation coefﬁcients between ESR, RF, anti-CCP and CRP in non-erosive patients.
Anti-CCP CRP ESR RF
rp -value rp -value rp -value rp -value
Anti-CCP ££ 20.16760 0.3215 0.06579 0.6989 0.66310 , 0.0001
CRP 20.16760 0.3215 ££ 0.09177 0.5890 0.34820 0.0347
ESR 0.06579 0.6989 0.09177 0.5890 ££ 0.12550 0.4592
RF 0.66310 , 0.0001 0.34820 0.0347 0.12550 0.4592 ££
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in early disease is highly predictive for more rapid
radiographic disease progression, a clinical hallmark of
aggressive RA (Visser et al. 2002, Orbach et al. 2002,
Vencovsky et al. 2003, Meyer et al. 2003, Forslind
et al. 2004). Thus, Vencovsky et al. studied the
predictive value of these autoantibodies in 64 patients
with early RA. It has been found that anti-CCP
positivity predicted progression of the Larsen score
over two years better then RF (Vencovsky et al. 2003).
These results were reinforced by Meyer et al. (2003)
who evaluated sensitivity, speciﬁcity, positive and
negative predictive value of anti-CCP in predicting
radiological progression 5 years after observation.
R e c e n t l y ,F o r s l i n de ta l .( 2 0 0 4 )r e p o r t e di na
prospective study that anti-CCP positive RA patients
had signiﬁcantly more joint damage than patients
without this antibody. Prediction analysis showed that
anti-CCP is an independent predictor of radiological
damage and progression. Visser et al. (2002)
described a clinical prediction model which includes
evaluation of anti-CCP antibodies and can discrimi-
nate between self limiting persistent non-erosive and
erosive arthritis. It have been claimed that anti- CCP
antibodies were strongly associated with erosive
arthritis more than RF (Odds ratio 4.56 vs. 2.99).
Our previous study on 101 patients with RA clariﬁed
that anti-CCP is superior to RF as a predictive test for
erosive RA (Orbach et al. 2002). The present study
conﬁrms previous suggestions that anti-CCP may
reﬂect the development of joint damage in RA and
anti-CCP is the best marker for erosive disease
compared to other evaluated markers including
MMP-3, RF, CRP and ESR. However, there are a
substantial number of patients with this predictor,
who still do not develop radiological damage in the
near future. Thus, no single variable can assure correct
diagnosis and prediction in an individual case, hence
combined scores have been sought.
The value of anti-CCPand different RF isotopes for
predicting the outcome of RA has been investigated
recently. Vallbracht et al. (2004) evaluated anti-CCP
antibodies and RF isotypes (IgM, IgA, IgG) in a large
population of RA patients. They showed that IgM RF
and anti-CCP are superior to other RF isotypes as
a screening method for RA, and determination of
both anti-CCP and RF isotopes contributes to the
prediction of clinical disease activity and radiological
damage. Additionally, up to 38.4% of IgM-RF
negative sera exhibited reactivity against CCP. There-
fore, in RF-negative patients detection of anti-CCP
has convincing importance.
The additional diagnostic value of anti-CCP is even
more impressive in the early course of RA, in patients
with severe joint destruction and in patients with very
active disease.
Thus, the study by Bus et al. (2003) in which the
presence of IgM-RF, IgA-RF, and anti-CCP was
evaluated, showed an association of IgA-RF and anti-
CCP with clinical signs of disease severity. Similarly,
analysis of RF isotopes (IgG-RF, IgA-RF, Ig M-RF)
and anti-CCP antibodies in pre-disease serum
samples revealed that anti-CCP and IgA-RF may
predict the development of RA (Rantapaa-Dahlqvist
et al. 2003).
Conclusion
The results of our study suggest that the presence of
anti-CCP antibodies has better diagnostic perform-
ance than MMP-3, RF, CRPand ESR in patients with
erosive RA. We have demonstrated that this antibody
is an independent predictor of radiological joint
damage. Furthermore, anti-CCP antibody testing
has been incorporated into newly proposed diagnostic
criteria for RA and proved to be strongly associated
with erosive disease. Further studies on larger patient
populations are needed to assess the value of anti-
CCP in clinical practice, especially for erosive RA.
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